Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK
The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.
You may also be interested in...
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.
Sosei Heptares' acquisition of Idorsia's ex-China APAC operations will give the Japan-UK group ready-made independent development and commercialization capabilities in Japan, accelerating by "five to 10 years" its goals in its home market, its CEO tells Scrip. The deal also brings a marketed drug and options to selected Idorsia pipeline assets.